23 completed. 23 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 23 |
| Phase 1 | 5 | Completed 5 |
Follow Recurrent Rectal Cancer: new trials by email Literature Review of Recurrent Rectal Cancer trials Research Report on Recurrent Rectal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab panitumumab, irinotecan hydrochloride, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Completed | John Hays | 16 | 2013-02-01 | 2025-02-05 |
| RO4929097 in Treating Patients With Metastatic Colorectal Cancer gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2010-05-01 | 2014-05-20 |
| Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer entinostat, azacitidine, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2010-04-01 | 2014-08-01 |
| Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PD-0332991 - Adult Solid Tumor, Adenocarcinoma of the Colon | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 304 | 2009-10-01 | 2021-03-11 |
| Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer sorafenib tosylate, bevacizumab - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 83 | 2009-09-01 | 2026-01-20 |
| Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment fluorouracil, leucovorin calcium, vorinostat - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Completed | Roswell Park Cancer Institute | 58 | 2009-07-01 | 2014-06-23 |
| Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma erlotinib hydrochloride, placebo, laboratory biomarker analysis - Adenomatous Polyp, Recurrent Colon Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 45 | 2008-07-01 | 2015-01-06 |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer pertuzumab, cetuximab, irinotecan hydrochloride - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2007-10-01 | 2015-03-31 |
| Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer dasatinib, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2007-07-01 | 2014-05-19 |
| VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer aflibercept - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 75 | 2006-10-01 | 2024-03-04 |
| Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery gemcitabine hydrochloride, floxuridine, proteomic profiling - Liver Metastases, Recurrent Colon Cancer | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 16 | 2005-06-13 | 2026-11-03 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer erlotinib hydrochloride, cetuximab, bevacizumab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2005-01-01 | 2014-06-11 |
| SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer ispinesib, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2005-01-01 | 2015-03-02 |
| Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer cetuximab, bevacizumab, oxaliplatin - Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon | Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2004-11-01 | 2015-07-27 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment oxaliplatin - Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 180 | 2004-10-01 | 2013-06-05 |
| 2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer PET Scan, CT Scan, fludeoxyglucose F 18 - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 21 | 2004-03-01 | 2016-03-02 |
| Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer cetuximab, bevacizumab, irinotecan hydrochloride - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 70 | 2003-12-01 | 2015-04-15 |
| Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer imatinib mesylate, laboratory biomarker analysis - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2002-05-01 | 2013-01-23 |
| Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver floxuridine, dexamethasone, oxaliplatin - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Completed | National Cancer Institute (NCI) | 75 | 2002-02-01 | 2013-07-16 |
Showing 20 of 23. Sign in to see all of them.
Colonic Neoplasms (23) · Rectal Neoplasms (23) · Carcinoma, Renal Cell (3) · Breast Neoplasms (2) · Breast Neoplasms, Male (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Esthesioneuroblastoma, Olfactory (2) · Nasopharyngeal Neoplasms (2) · Pancreatic Neoplasms (2) · Salivary Gland Neoplasms (2) · Teratoma (2) · Testicular Neoplasms (2) · Adenomatous Polyps (1) · Adrenocortical Carcinoma (1)
Colonic Diseases (23) · Digestive System Diseases (23) · Digestive System Neoplasms (23) · Gastrointestinal Diseases (23) · Intestinal Diseases (23) · Intestinal Neoplasms (23) · Neoplasms by Site (23) · Rectal Diseases (23) · Gastrointestinal Neoplasms (22) · Neoplasms (22) · Colorectal Neoplasms (21) · Neoplasms by Histologic Type (6) · Male Urogenital Diseases (5) · Neoplasms, Glandular and Epithelial (5) · Urogenital Diseases (5)
Bevacizumab (4) · Cetuximab (4) · Irinotecan (4) · Leucovorin (4) · Erlotinib Hydrochloride (3) · Floxuridine (3) · Fluorouracil (3) · Oxaliplatin (3) · Fluorodeoxyglucose F18 (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 2C4 antibody (1) · Azacitidine (1) · Calcium Dobesilate (1) · Capecitabine (1) · Chromatography, Liquid (1)
National Cancer Institute (NCI) (15) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · City of Hope Medical Center (1) · John Hays (1) · National Institutes of Health Clinical Center (CC) (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Sanjiv Sam Gambhir (1)
United States (21) · Canada (2)
Alain Mita (1) · Allyson Ocean (1) · Amit Oza (1) · Axel Grothey, MD (1) · Edward Martin, MD (1) · H. Richard Alexander, Jr. (1) · Hedy Kindler (1) · James Abbruzzese (1) · Jeffrey Wong (1) · John Hays, MD (1) · Jonathan Strosberg (1) · Kimmie Ng (1) · Leonard Saltz (1) · Malcolm Moore (1) · Nilofer Azad (1)
PMID 17634125, PMID 20048179, PMID 21208843, PMID 24583822, PMID 25965900, PMID 26062933, PMID 26611425, PMID 30850872, PMID 32201506, PMID 32641862, PMID 32692450
N01CM62201 (2), U10CA025224 (2), N01CM00038 (1), N01CM00099 (1), N01CM17003 (1), N01CM17101 (1), N01CM17102 (1), N01CM17103 (1), N01CM17105 (1), N01CM17107 (1), N01CM62202 (1), N01CM62203 (1), N01CM62204 (1), N01CM62208 (1), N01CN35160 (1)